The new contract –terms of which were not disclosed – will see the Swedish contract manufacturing organisation’s (CMO) semi-solid products unit make Shact – which is used to alleviate discomfort and pain during IUD insertion - at its facility in Karlskoga.
Recipharm will manufacture Shact along with a proprietary application device developed to simplify topical application in the cervix and uterus in a long term deal that will extend to any country in which the drug is launched.
The manufacturing contract is the first Recipharm has announced since it completed its initial public offering on the NASDAQOMX exchange on April 3.